Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sequist, L
Fidias, P
Temel, J
Kennedy, E
Ostler, P
Rabin, M
Huberman, M
Keck, J
Brown, G
Lynch, T
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Telik Inc, Palo Alto, CA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [1] Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Sequist, LV
    Fidias, P
    Temel, J
    Kennedy, BA
    Ostler, PA
    Rabin, MS
    Huberman, M
    Keck, J
    Brown, GL
    Lynch, TJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 689S - 689S
  • [2] Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC)
    Papadimitrakopoulou, V
    Edelman, M
    Zinner, R
    Blumenschein, G
    Jones, S
    Willcutt, N
    Keck, J
    Brown, G
    Burris, H
    LUNG CANCER, 2005, 49 : S262 - S263
  • [3] Paclitaxel and Carboplatin in combination with Gemcitabine (PCG): A phase I-II trial in non-small cell lung cancer (NSCLC)
    Favaretto, A
    Paccagnella, A
    Tumolo, S
    Barbieri, F
    Ceresoli, G
    Gulisano, M
    Oniga, F
    Bearz, A
    Fiorentino, MV
    ANNALS OF ONCOLOGY, 1998, 9 : 91 - 91
  • [4] Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
    Lynch, T. J.
    Bondarenko, I. N.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R. T.
    Sebastian, M.
    Siegel, J.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer
    Shipley, D.
    Spigel, D. R.
    Cavanaugh, C.
    Moore, Y.
    Hainsworth, J. D.
    Jones, S.
    Burris, H. A., III
    Sade, L.
    Yardley, D. A.
    Greco, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results
    Thompson, D. S.
    Spigel, D. R.
    Hainsworth, J. D.
    Jones, S. F.
    Burris, H. A., III
    Sade, L.
    Raefsky, E.
    Greco, F. A.
    Yun, S.
    Noursalehi, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I/II trial of docetaxel (D) and Carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Giannakakis, T
    Papadouris, S
    Kourousis, C
    Kalbakis, NK
    Tzianni, V
    Lidaki, E
    Androulakis, N
    Souklakos, J
    Sarra, E
    Georgoulias, V
    ANNALS OF ONCOLOGY, 1998, 9 : 94 - 94
  • [8] A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Allerton, J. P.
    Hagenstad, C. T.
    Webb, R. T.
    Smith, G. B.
    Birch, R.
    Goggins, T. F.
    Katakkar, S. B.
    Khan, W.
    Mehta, N. D.
    Greco, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 395S - 395S
  • [9] Phase II dose-ranging study of TLK286 a novel glutathione analog prodrug, in combination with cisplatin as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Burris, HA
    Edelman, MJ
    Stewart, D
    Fossella, F
    Jones, S
    Willcutt, N
    Keck, JG
    Brown, GL
    Papadimitrakopoulou, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 651S - 651S
  • [10] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
12345